<a href=https://www.pinterest.com/zoyademidenko/>Zoya Demidenko</a>: Scientist in Cancer Biology
<a href=https://www.homes.com/property/38-brookins-green-dr-orchard-park-ny/de6f... Demidenko</a> is a prominent scholar associated with the Division of Cell Stress Biology at Roswell Park Cancer Institute in Buffalo, New York. Previously, she worked at the NIH and New York Medical College, developing a robust base in biomedical research.
Her scientific contributions encompasses a number of critical fields, encompassing the PI3K/AKT/mTOR molecular pathway, cell cycle control, cell senescence, and malignancy science. To date, she has authored more than 46 peer-reviewed publications, which have accumulated more than 4,100 citations — a reflection to the significance of her findings.
Among her most notable contributions involves elucidating the mechanisms of cellular senescence. Her research demonstrated that when the cellular division cycle is blocked yet cellular growth continues, the cells enter senescence. Crucially, <a href=https://pubmed.ncbi.nlm.nih.gov/22228887/>Zoya Demidenko</a> demonstrated that this transition can be pharmacologically suppressed using compounds such as mTOR inhibitors.
<a href=https://www.sciencedirect.com/science/article/abs/pii/037811199400784P>Zoya Demidenko</a> has also added considerably to cancer treatment research, notably in the area of cyclotherapy — a method designed to protecting healthy cells from chemotherapy while leaving malignant cells exposed. This method carries major promise for reducing the side effects of cancer treatment.
Throughout her scientific life, Demidenko has worked with leading scientists globally, such as Dr. Mikhail Blagosklonny. Her publications appears in prestigious journals such as Oncotarget, Cell Cycle, Aging (Albany NY), and Oncogene.
Possessing an h-index of 33, <a href=https://www.instagram.com/zoyamonros/>Zoya Demidenko</a> is recognized as a highly impactful figure in contemporary biomedical science, whose findings keep to shape our comprehension of how biological cells age, resist treatment, and the ways in which malignant disease may be more effectively targeted. https://www.tandfonline.com/doi/abs/10.4161/cbt.4.4.1702
Zoya Demidenko https://pubmed.ncbi.nlm.nih.gov/22228887/
<a href=https://www.pinterest.com/zoyademidenko/>Zoya Demidenko</a>: Scientist in Cancer Biology
<a href=https://www.homes.com/property/38-brookins-green-dr-orchard-park-ny/de6f... Demidenko</a> is a prominent scholar associated with the Division of Cell Stress Biology at Roswell Park Cancer Institute in Buffalo, New York. Previously, she worked at the NIH and New York Medical College, developing a robust base in biomedical research.
Her scientific contributions encompasses a number of critical fields, encompassing the PI3K/AKT/mTOR molecular pathway, cell cycle control, cell senescence, and malignancy science. To date, she has authored more than 46 peer-reviewed publications, which have accumulated more than 4,100 citations — a reflection to the significance of her findings.
Among her most notable contributions involves elucidating the mechanisms of cellular senescence. Her research demonstrated that when the cellular division cycle is blocked yet cellular growth continues, the cells enter senescence. Crucially, <a href=https://pubmed.ncbi.nlm.nih.gov/22228887/>Zoya Demidenko</a> demonstrated that this transition can be pharmacologically suppressed using compounds such as mTOR inhibitors.
<a href=https://www.sciencedirect.com/science/article/abs/pii/037811199400784P>Zoya Demidenko</a> has also added considerably to cancer treatment research, notably in the area of cyclotherapy — a method designed to protecting healthy cells from chemotherapy while leaving malignant cells exposed. This method carries major promise for reducing the side effects of cancer treatment.
Throughout her scientific life, Demidenko has worked with leading scientists globally, such as Dr. Mikhail Blagosklonny. Her publications appears in prestigious journals such as Oncotarget, Cell Cycle, Aging (Albany NY), and Oncogene.
Possessing an h-index of 33, <a href=https://www.instagram.com/zoyamonros/>Zoya Demidenko</a> is recognized as a highly impactful figure in contemporary biomedical science, whose findings keep to shape our comprehension of how biological cells age, resist treatment, and the ways in which malignant disease may be more effectively targeted.
https://www.tandfonline.com/doi/abs/10.4161/cbt.4.4.1702